<Important Notes>
The forward-looking statements contained in this presentation are based on the Company’s assumptions and beliefs in the light of information currently available to it and involves known and unknown risks and uncertainties. Accordingly, there is a possibility that actual results and development programs may differ largely from these forecasts, due to a variety of factors. This report contains information on pharmaceutical products (including those under development), and the content of this report is not intended for medical promotion or medical advice. This translation is provided solely as a reference material. In the case of any discrepancy between the two versions, the original Japanese version shall prevail.
- December 4 2025 ASKA Pharmaceutical Launches LEUPRORELIN ACETATE SR FOR INJECTION KIT
- November 5 2025 PPMX and ASKA Pharmaceutical Sign Joint Research Agreement to Aim to Create New Antibody Drugs
- October 20 2025 ASKA Obtains Marketing Authorization of Emergency Contraceptive Pill NORLEVO® as Switch to OTC Use and Daiichi Sankyo Healthcare Handles Distribution and Sales
- September 24 2025 Personnel Change of ASKA Pharmaceutical
- August 22 2025 Personnel Changes of ASKA Pharmaceutical
- July 15 2025 Call for Drug Discovery Research Proposal 2025 of ASKA pharmaceutical
- July 14 2025 ASKA to Open ZEB Certified Community Center “arca” at its Iwaki Factory
- June 30 2025 ASKA Launches Oral Contraceptive Slinda® 28 Tablets in Japan
- June 25 2025 ASKA to Initiate Domestic Phase III Clinical Trial of Relugolix Combination Tablet for Endometriosis
- June 24 2025 Personnel Changes of ASKA Pharmaceutical Holdings Subsidiaries
- June 20 2025 Personnel Change of ASKA Pharmaceutical
- May 19 2025 ASKA Obtains Manufacturing and Marketing Approval for Oral Contraceptive Slinda® 28 Tablets in Japan
- May 15 2025 ASKA Files Application with Japanese Authorities for Manufacturing and Marketing Approval of Emergency Contraceptive Pill “NORLEVO” as Switch OTC Drug
- April 24 2025 Personnel Changes in Board Members and Corporate Officers of ASKA Pharmaceutical Holdings’ Subsidiaries
- April 24 2025 Change in Personnel and Member of Board of Directors’ Responsibilities of ASKA Pharmaceutical
- April 24 2025 Changes in Organizational, Personnel, and Member of Board of Directors’ Responsibilities of ASKA Pharmaceutical
- April 23 2025 ASKA Announces Phase III Clinical Trial Result of TRM-270
- March 12 2025 ASKA Pharmaceutical Co., Ltd. R&D Presentation for Investors[PDF](held on March 12,2025)
- March 10 2025 ASKA Pharmaceutical Holdings Group Recognized as White 500 Enterprise for Seventh Consecutive Year
- March 10 2025 ASKA Initiates Phase I II Clinical Trial of Drospirenone Agent (LPRI-CF113) in Japan
- February 21 2025 Organizational and Personnel Changes of ASKA Pharmaceutical
- February 3 2025 Notice Concerning Consolidation of Ha Tay Pharmaceutical Joint Stock Company as Consolidated Subsidiary
- January 28 2025 ASKA and SUSMED Start Specified Clinical Trial Using Digital Therapeutics App Designed for Patients with PMS/PMDD
- January 14 2025 Veneno Technologies and ASKA Signed a Joint Research Agreement for the Development of Novel Ion Channel Therapeutics
- December 27 2024 Additional Indication of Sclerotherapy of Venous Malformations for OLDAMIN for Injection 1g in Japan
- December 25 2024 ASKA Pharmaceutical and Insud Pharma Have Entered into a New License Agreement
- December 16 2024 ASKA Initiates Domestic Phase III Clinical Trial of Relugolix Combination Tablet
- November 25 2024 ASKA Pharmaceutical Terminates Joint Development and Option Agreement for a PMS/PMDD Agent with Renascience
- November 13 2024 ASKA Pharmaceutical Presents the Results of Phase III Clinical Trial for Oral Contraceptive LF111 at a Conference
- September 24 2024 TechDoctor and ASKA Pharmaceutical Launch Joint Research on Dysmenorrhea in Cooperation with Healthcare App "4MOON"
For the previous news releases, please refer to the website of ASKA Pharmaceutical Holdings Co., Ltd.


